Bumetanide
Brand names: Bumetanide
At a glance
- Medicare prescriptions, 2024
- 1,806,764
- Medicare drug cost
- $59.2M
- Average cost per prescription
- $32.77
- Clinicians who prescribed it
- 53,824
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Bumetanide tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient's needs ( see DOSAGE AND ADMINISTRATION ).
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 20.8%
- Internal Medicine 20.6%
- Nurse Practitioners 20.2%
- Cardiology 12.7%
- Nephrology (Kidney) 8.2%
- Physician Assistants 4.7%
- Interventional Cardiology 4.2%
- Geriatric Medicine 2.2%
- Heart Failure & Transplant Cardiology 1.6%
- General Practice 1.3%
- Hospitalist 0.9%
- Cardiac Electrophysiology 0.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 27% from 2019 to 2024.
Biggest change by state since 2019
- Wisconsin +68%
- Arkansas +66%
- North Dakota +60%
- Iowa +59%
- New Mexico +58%
- Oregon (smallest change) −8%
- Massachusetts (smallest change) −7%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg | white round tablet, 6 mm | AC AND 163 |
Northstar Rx LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg | white round tablet, 7 mm | UPARROWHEAD31 |
| 1 mg | yellow round tablet, 8 mm | UPARROWHEAD32 |
| 2 mg | white round tablet, 10 mm | UPARROWHEAD33 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 2 mg | white round tablet, 10 mm | UPARROWHEAD33 |
Sandoz Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg | green round tablet, 6 mm | E 128 |
| 1 mg | yellow round tablet, 8 mm | E 129 |
| 2 mg | brown round tablet, 10 mm | E 130 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.